Eurofins Dermscan Poland
Gdansk, Poland
NCT Number: NCT06819709
The purpose of this study is to examine the effects of a botanical moisturizer, an oral supplement, and an unscented soap on eczema severity, itch, mood, and various skin measures (such as skin hydration) in those with mild to moderate eczema.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Gdansk, Poland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention includes 3 products:
Time frame: 8 weeks
Change in eczema severity was assessed using SCORAD (SCOring of Atopic Dermatitis).
A. First, the spread of eczema on different body areas is assessed by the investigator and calculated as a percent, where the maximum is 100%.
B. Second, the intensity of skin redness, swelling, oozing, scratch marks, skin thickening and dryness is scored by the investigator from 0 to 3, where 0 is none, 1 is mild, 2 is moderate, and 3 is severe.
C. Finally, for the subjective score, participants are asked to report the intensity of symptoms (itch and sleeplessness) from 0 to 10, where 0 is no itch or no sleeplessness, and 10 is the worst imaginable itch or insomnia sleeplessness.
The total score of the objective SCORAD is obtained with the following formula: SCORAD = A/5 + 7 B/2 + C
Time frame: 8 weeks
Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI). Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores.
Time frame: 4 weeks
Change in localized eczema severity is assessed with the Eczema Area and Severity Index (EASI). Skin redness, elevation, scratching, and thickening are assessed by the investigator on a scale of 0 to 3, where 0 is none, 1 is mild, 2 is moderate, 3 is severe. The localized EASI is the sum of these scores.
Time frame: 4 weeks
Change in skin hydration is assessed with a Corneometer.
Time frame: 8 weeks
Change in skin hydration is assessed with a Corneometer.
Time frame: 4 weeks
Change in transepidermal water loss is assessed with a Tewameter TM 300
Time frame: 8 weeks
Change in transepidermal water loss is assessed with a Tewameter TM 300
Time frame: 4 weeks
Change in desquamation is assessed with D-Squam®.
Time frame: 8 weeks
Change in desquamation is assessed with D-Squam®.
Time frame: 4 weeks
Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form).
Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely.
Time frame: 8 weeks
Change in mood is assessed with the PANAS-SF (Positive and Negative Affect Schedule- Short Form).
Participants are asked to evaluate the degree to which they experienced components of positive and negative affect : Interested, Distressed, Excited, Upset, Strong, Guilty, Scared, Hostile, Enthusiastic, Proud, Irritable, Alert, Ashamed, Inspired, Nervous, Determined, Attentive, Jittery, Active, and Afraid. A 5-point scale was used where 1 is very slightly or not at all, 2 is a little, 3 is moderately, 4 is quite a bit, and 5 is extremely.
Codex Labs Corporation
Industry
Clinical and Instrumental Efficacy Evaluation of One Cosmetic Oral Supplement - Eczema Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06804070
Atopic Dermatitis (Eczema), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Gdansk, Poland
View Trial DetailsNCT07670676
Atopic Dermatitis (Eczema), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Gdansk, Poland
View Trial DetailsNCT06998056
Atopic Dermatitis (Eczema), Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT07046039
Acne Vulgaris, Acneiform Eruptions
Jeddah, Saudi Arabia
View Trial Details